FDA Authorizes Marketing of 20 ZYNs: What the Decision Means

Back in January 2025, the U.S. Food and Drug Administration (FDA) made a groundbreaking decision to grant its first nicotine pouch marketing authorization to 20 ZYN products.  

These pouches from ZYN’s classic 3mg and 6mg range underwent rigorous scientific review to evaluate their risk profile relative to other tobacco products as well as their potential benefits and risks at the population level.

The FDA’s announcement signaled to Americans (and the industry at large) that these tobacco leaf-free products met the stringent statutory standard for marketing authorization under the 2009 Family Smoking Prevention & Tobacco Control Act. 

Update: As of June 30, 2026, the FDA has taken this one step further, authorizing these 20 ZYNs as Modified Risk Tobacco Products (MRTPs).

The FDA-authorized claim states: “Using ZYN instead of cigarettes puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

"This is a pivotal step for the nicotine pouch category and an important development for adult smokers considering different tobacco products," said Markus Lindblad, Communications Director at Northerner.  

The FDA’s marketing authorization, or Marketing Granted Order (MGO), allowed the 20 products to be legally marketed in the United States. MRTP authorization required a separate FDA application and review. 

As part of the PMTA review, the FDA assessed potential population-level benefits and risks, determining that the 20 ZYN nicotine pouches contain “substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products.” 

Matthew Farrelly, Ph.D., from the FDA’s Center for Tobacco Products, reinforced this point: 

The data shows that these nicotine pouch products meet the bar by benefiting adults who smoke cigarettes or use smokeless tobacco and completely switch to these products.

Matthew Farrelly

FDA’s Center for Tobacco Products

The 20 authorized products include both 3mg and 6mg variants of ZYN’s Wintergreen, Spearmint, Cool Mint, Peppermint, Cinnamon, Coffee, Citrus, Chill, Smooth, and Menthol nicotine pouches.  

It’s worth noting that ZYN’s new flavors and ZYN Ultra range are covered by a separate pending application. 

Industry analysts hailed ZYN’s MGO as a “game changer,” and suggested it could provide a regulatory benchmark for similar products from other manufacturers going forward.  

This has been reinforced by the FDA’s new nicotine pouch enforcement priorities, which we’ve already begun to see gradually open the American market for brands that follow the rules. 

"This marks a significant step forward for the industry," Lindblad added. "The U.S. is now catching up with the EU in terms of ensuring smokers on both continents have access to wider range of smoke-free products. This is a day to celebrate." 

One thing is clear: the FDA’s investigation and subsequent authorization of ZYN has established an important precedent for the scientific review of nicotine pouches. 

The FDA’s subsequent MRTP authorization adds another important layer to that decision, allowing these 20 ZYN products to carry a specific reduced-risk claim when used instead of cigarettes. 

The challenge remains to balance public health with innovation, ensuring that adult consumers have access to safer alternatives without unnecessary barriers. 

The future of nicotine products is evolving and, here at Northerner, we believe these FDA decisions are just the beginning.